CD4+ Th1 to the rescue in HER-2+ breast cancer. Academic Article uri icon

Overview

abstract

  • HER2 overexpression leads to downregulation of MHC class-I. CD4+ Th1 cytokines, IFNγ and TNFα, and monoclonal antibodies, trastuzumab and pertuzumab, restore MHC class-I expression, and enable CD8+ recognition and cytolysis. Restoration of the anti-HER2 CD4+ Th1 immune response in combination with HER2 targeted therapy appear to be critical to successful anti-HER2 CD8+ immunotherapy.

publication date

  • May 2, 2018

Identity

PubMed Central ID

  • PMC6791441

Scopus Document Identifier

  • 85046464839

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2015.1078062

PubMed ID

  • 31646065

Additional Document Info

volume

  • 8

issue

  • 10